Example: bachelor of science
NEW ZEALAND DATA SHEET - Medsafe
NEW ZEALAND DATA SHEET 1. PRODUCT NAME ENBREL (Etanercept) 25 mg powder for injection and water for injections . ENBREL (Etanercept) 25 mg and 50 mg solution for injection in pre-filled syringe
Tags:
Information
Domain:
Source:
Link to this page:
Documents from same domain
ADVANTAN Presentation Uses - Medsafe
www.medsafe.govt.nzADVANTAN® Data Sheet Page 1 of 9 ADVANTAN® Methylprednisolone aceponate 0.1% ointment/cream . Presentation 1 g cream or ointment contains 1 mg (0.1%) methylprednisolone aceponate.
LOXALATE 1. Product Name - Medsafe Home Page
www.medsafe.govt.nzPage 5of 21 at risk, such as the elderly, or patients with cirrhosis, or if used in combination with other medications which may cause hyponatraemia.
DATA SHEET 1 CLEXANE AND CLEXANE FORTE ... - …
www.medsafe.govt.nzNew Zealand Data Sheet June 2017 . clexane-clexane-forte-ccdsv13-dsv18-16jun17 Page 2 . 100 mg injection enoxaparin sodium 100mg (equivalent to …
SEPTANEST Articaine hydrochloride 4% with …
www.medsafe.govt.nzSEPTANEST Articaine hydrochloride 4% with adrenaline 1:100,000 Injection for local and regional dental anaesthesia DESCRIPTION SEPTANEST is a sterile aqueous solution that contains articaine hydrochloride 4% (40 mg/mL) with adrenaline acid tartrate in a 1:100,000 strength.
BOOSTRIX - Medsafe Home Page
www.medsafe.govt.nz1 BOOSTRIX®. Combined diphtheria, tetanus, acellular pertussis (dTpa) vaccine . CONSUMER MEDICINE INFORMATION WHAT IS IN THIS LEAFLET? This leaflet answers some of the common questions about BOOSTRIX vaccine.
NEW ZEALAND DATA SHEET - Medsafe
www.medsafe.govt.nzNEW ZEALAND DATA SHEET Cymevene ® DS 170831 2 of 26 Caution: Cymevene must only be administered by IV infusion over 1 hour, preferably via a
Edition Draft - Medsafe
www.medsafe.govt.nzPart 4, Ed Draft Page 2 of 9 Section 1: Good Manufacturing Practice Documentation 1.1. When is GMP Documentation Required? Medsafe requires evidence of Good Manufacturing Practice (GMP) compliance for
Data Sheet 1 PRODUCT NAME 2 QUALITATIVE AND …
www.medsafe.govt.nzNew Zealand Data Sheet 31 July 2017 Lantus – insulin glargine lantus-ccdsv19-dsv11-31jul17 Page 1 Data Sheet 1 PRODUCT NAME Lantus 100 IU/mL solution for injection in 10 …
NEW ZEALAND DATA SHEET MESTINON® - Medsafe
www.medsafe.govt.nzNEW ZEALAND DATA SHEET MESTINON® MESTINON Page 4 of 8 As the severity of myasthenia gravis often fluctuates considerably, particular care is required to
DATA SHEET PREDNISONE - Medsafe
www.medsafe.govt.nz• Epilepsy and/or seizure disorder • Peptic ulceration • Previous steroid myopathy • Tuberculosis • Patients with myasthenia gravis receiving anticholinesterase therapy since
Related documents
The Bath Ankylosing Spondylitis Disease Activity ... - BASDAI
basdai.comThe Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Please place a mark on each line below to indicate your answer to each question relating to
New Brunswick Drug Plans Special Authorization Criteria ...
www2.gnb.ca• For the treatment of patients with moderate to severe ankylosing spondylitis (e.g. Bath AS Disease Activity Index (BASDAI) score ≥ 4 on 10 point scale) who:
Validación del índice compuesto DAPSA (Disease Activity ...
revistasar.org.arJ. Gallino Yanzi et al • Rev Arg Reumatol. 2016;27(3): 23-29 25 of Life)23, para capacidad funcional HAQ-A (Health Assessment Questionnaire Argentinean version)24 y BASFI (Bath Ankylosing Spondylitis Functional Index)25 y para actividad de la enfermedad axial BASDAI.
Bath Ankylosing Spondylitis Disease Activity Index* - BASDAI
basdai.comVersion1 AnkSponBASFI18/09/2003.doc Bath Ankylosing Spondylitis Functional Index* BASFI *Calin et al. J Rheumatol 1994 21; 2281-85 Date_____ Patient Name_____ Please ...
Bath Ankylosing Spondylitis Disease Activity Index Intérêt ...
www.rhumatologie.asso.frSociété Française de Rhumatologie Critères d'activité Version PDF Envoyer à un ami Imprimer NOM : DATE : Bath Ankylosing Spondylitis Disease Activity Index
271 強直性脊椎炎 - mhlw.go.jp
www.mhlw.go.jp＜重症度基準＞ （重症例判断基準） 下記のいずれかを満たす場合を重症例として対象とする。 ・BASDAIスコアが4以上 かつCRP が1.5 mg/dl以上。
NOTES REGARDING THE EXCEPTION DRUG STATUS (EDS) …
formulary.drugplan.health.gov.sk.ca1 APPENDIX A EXCEPTION DRUG STATUS PROGRAM . NOTES REGARDING THE EXCEPTION DRUG STATUS (EDS) PROGRAM • Duly licensed practitioners prescribing within their …
Instrumentos de Avaliação em Espondilite Anquilosante
www.scielo.brartigo dE rEvisão rEviEw articlE RESUMO A espondilite anquilosante (EA) é uma doença inflamatória crônica caracterizada por acometimento predominante do esqueleto axial. Ocorre de forma insidiosa e é potencialmente debilitante, levando